- Home
- AUST vs IPA Comparison
AUST vs IPA Comparison
Compare AUST & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- IPA
- Stock Information
- Founded
- AUST 2020
- IPA 1983
- Country
- AUST Canada
- IPA Canada
- Employees
- AUST N/A
- IPA N/A
- Industry
- AUST
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- IPA Health Care
- Exchange
- AUST Nasdaq
- IPA Nasdaq
- Market Cap
- AUST 21.5M
- IPA 19.3M
- IPO Year
- AUST 2022
- IPA 2017
- Fundamental
- Price
- AUST $1.30
- IPA $0.38
- Analyst Decision
- AUST
- IPA Strong Buy
- Analyst Count
- AUST 0
- IPA 2
- Target Price
- AUST N/A
- IPA $4.00
- AVG Volume (30 Days)
- AUST 121.8K
- IPA 2.3M
- Earning Date
- AUST 05-07-2025
- IPA 03-28-2025
- Dividend Yield
- AUST N/A
- IPA N/A
- EPS Growth
- AUST N/A
- IPA N/A
- EPS
- AUST N/A
- IPA N/A
- Revenue
- AUST N/A
- IPA $16,581,105.00
- Revenue This Year
- AUST N/A
- IPA $1.88
- Revenue Next Year
- AUST N/A
- IPA $9.90
- P/E Ratio
- AUST N/A
- IPA N/A
- Revenue Growth
- AUST N/A
- IPA 1.35
- 52 Week Low
- AUST $0.79
- IPA $0.27
- 52 Week High
- AUST $3.19
- IPA $1.50
- Technical
- Relative Strength Index (RSI)
- AUST 45.85
- IPA 44.80
- Support Level
- AUST $1.23
- IPA $0.32
- Resistance Level
- AUST $1.53
- IPA $0.46
- Average True Range (ATR)
- AUST 0.16
- IPA 0.05
- MACD
- AUST -0.02
- IPA -0.00
- Stochastic Oscillator
- AUST 14.99
- IPA 42.70
About AUST Austin Gold Corp.
Austin Gold Corp is a gold exploration and development company focused on gold targets and making district-scale gold discoveries in Nevada. Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Fourmile Basin in Nye County.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.